Get the Weekly Intelligence Brief — top committee picks every Sunday.
GMAB · NASDAQ · STOCK

Genmab A/S

Healthcare Updated August 11, 2026
$30.82
52W $21.17 – $35.43
60/100
$18.94B
24.0
0.69
AI Committee Verdict
Buy
60/100
Conviction: Moderate · 60% agreement · 5 analysts
Moderate

Is GMAB Bullish or Bearish?

Bullish. Innellis AI committee rates Genmab A/S (GMAB) Buy with a composite score of 60/100 , based on 5 analysts with 60% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +14.75 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -5.25 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.15 across 13 articles, 14d) — News
Bear Case
  • EPS declining -25.3% YoY despite any revenue growth — Growth
  • RSI at 73 is in overbought territory — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
60/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 45%
of 192 Healthcare peers
Value Analyst neutral
58 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
Growth Analyst neutral
42 / 100 · Moderate confidence
Moderate growth -- present but not remarkable
− EPS declining -25.3% YoY despite any revenue growth
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 73 is in overbought territory
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
63 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.15 across 13 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
72.5
Overbought
MACD Histogram
0.153
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$30.36
Resistance
$33.65
Bollinger %B
0.97
Inside Bands
Price vs Moving Averages
EMA 9
$29.99 Above
EMA 21
$29.25 Above
EMA 50
$28.29 Above
EMA 200
$27.69 Above

Fundamental Analysis

Valuation
79
Profitability
62
Financial Health
90
Cash Flow
70
Valuation
P/E Ratio 24.0×
P/B Ratio 3.17×
PEG Ratio -0.28
Dividend Yield 0.00%
52W High $35.43
52W Low $21.17
Quality & Growth
ROE 1652.1%
ROA 750.4%
Gross Margin 3991.8%
Operating Margin 1381.2%
Revenue Growth YoY
Debt / Equity 0.89
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 24.0 (inexpensive relative to a 15-40x range); Price-to-book of 3.2x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 16.5%; Return on assets of 7.5%; Net margin of 8.2%; Gross margin of 39.9%; Current ratio of 2.46 (healthy short-term liquidity); Debt-to-equity of 0.89; Free cash flow per share is positive (1.42); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full GMAB Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore GMAB Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime